Senior commercial launch experts supporting emerging biotech and biopharma from clinical development to commercialization and first-time U.S. launches.
Our experts bring backgrounds from
2 in 3 biotech launches underperform forecast.*
70% of commercially insured patients faced a coverage denial when starting a new branded medicine.*
Without early governance and cross-functional alignment, launch execution risk builds before market entry.
Real operators who have led commercialization work from pipeline to market.
Advice grounded in U.S. and global launches, not generic consulting playbooks.
Offering the advantages of agility without the complexities and overhead of larger firms.
Focused support that flexes as priorities, risks, and execution needs evolve.
Our InvenioNexT Performance Model supports the launch lifecycle from pre-launch planning through post-launch performance.
Founder & CEO
Biopharma senior leader with 20+ years of experience leading products from pipeline to market across oncology and specialty care. U.S. and global blockbuster launches and business growth. Senior leadership team member guiding financial precision across portfolios.
Data Scientist
Oxford-trained applied health data scientist and technology leader building AI-supported decision tools across global health and reproductive care. Experience spanning clinical risk modelling, external validation, product architecture, and deployment-ready systems for practical, high-impact healthcare decisions.
We'll follow up to discuss readiness, commercial execution, and post-launch performance.